[{"notes_id":"1_1890","category":"1","subcategory":"1","title":"ACE inhibitors","body":"Angiotensin-converting enzyme (ACE) inhibitors are now the established first-line treatment in younger patients with hypertension and are also extensively used to treat heart failure. They are known to be less effective in treating hypertensive Afro-Caribbean patients. ACE inhibitors are also used to treat diabetic nephropathy and have a role in the secondary prevention of ischaemic heart disease.<br \/><br \/>Mechanism of action:<br \/><ul><li>inhibits the conversion angiotensin I to angiotensin II<ul><li>&rarr; decrease in angiotensin II levels &rarr; to vasodilation and reduced blood pressure<\/li><li>&rarr; decrease in angiotensin II levels &rarr; reduced stimulation for aldosterone release &rarr; decrease in sodium and water retention by the kidneys<\/li><\/ul><\/li><li>renoprotective mechanism<ul><li>angiotensin II constricts the efferent glomerular arterioles <\/li><li>ACE inhibitors therefore lead to <span class=\"concept\" data-cid=\"12098\">dilation of the efferent arterioles<\/span> &rarr; reduced glomerular capillary pressure &rarr; decreased mechanical stress on the delicate filtration barriers of the glomeruli<\/li><li>this is particularly important in diabetic nephropathy<\/li><\/ul><\/li><li><span class=\"concept\" data-cid=\"5284\">ACE inhibitors are activated by phase 1 metabolism in the liver <\/span><\/li><\/ul><br \/>Side-effects:<br \/><ul><li>cough<ul><li>occurs in around 15% of patients and may occur up to a year after starting treatment<\/li><li>thought to be due to <span class=\"concept\" data-cid=\"2034\">increased bradykinin levels<\/span><\/li><\/ul><\/li><li><span class=\"concept\" data-cid=\"2270\">angioedema<\/span>: may occur up to a year after starting treatment<\/li><li><span class=\"concept\" data-cid=\"5266\">hyperkalaemia<\/span><\/li><li>first-dose hypotension: more common in patients taking diuretics<\/li><\/ul><br \/>Cautions and contraindications<br \/><ul><li><span class=\"concept\" data-cid=\"3346\">pregnancy<\/span> and breastfeeding - avoid<\/li><li><span class=\"concept\" data-cid=\"10496\">renovascular disease<\/span> - may result in renal impairment<\/li><li><span class=\"concept\" data-cid=\"3361\">aortic stenosis<\/span> - may result in hypotension<\/li><li>hereditary of idiopathic angioedema<\/li><li><span class=\"concept\" data-cid=\"10244\">specialist advice should be sought before starting ACE inhibitors in patients with a potassium >= 5.0 mmol\/L<\/span><\/li><\/ul><br \/>Interactions<br \/><ul><li>patients receiving high-dose diuretic therapy (more than 80 mg of furosemide a day)<ul><li>significantly increases the risk of hypotension<\/li><\/ul><\/li><\/ul><br \/>Monitoring<br \/><ul><li><span class=\"concept\" data-cid=\"3883\">urea and electrolytes should be checked before treatment is initiated and after increasing the dose<\/span><ul><li>a rise in the creatinine and potassium may be expected after starting ACE inhibitors<\/li><li><span class=\"concept\" data-cid=\"3884\">acceptable changes are an increase in serum creatinine, up to 30% from baseline<\/span> and an increase in potassium up to 5.5 mmol\/l.<\/li><li>significant renal impairment may occur in patients who have undiagnosed <span class=\"concept\" data-cid=\"10906\">bilateral renal artery stenosis<\/span><\/li><\/ul><\/li><\/ul><br \/>Examples of common ACE inhibitors<br \/><ul><li>ramipril<\/li><li>enalapril<\/li><li>lisinopril<\/li><\/ul><br \/><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd566b.png'><img class='ajaximage' src='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd566.png'\/><\/a><\/td><\/tr><tr><td valign='top' align='left'><\/td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd566b.png'><img src='https:\/\/d32xxyeh8kfs8k.cloudfront.net\/css\/images\/mag_glass.png'\/><\/a><\/td><\/tr><\/table><\/CENTER><div class='imagetext'>Flow chart showing the management of hypertension as per current NICE guideliness<\/div>","notes_hash":"b9bc8382b304704c258a375c1f412b6c","knowledge_graph_node_id_link":10620,"links":"<table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_471\" data-linkid=\"471\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_471\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">63<\/span><button type=\"button\" style=\"\" id=\"link_dislike_471\" data-linkid=\"471\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_471\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">41<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/cg182\/chapter\/1-recommendations\">2014 Chronic kidney disease guidelines<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>BNF<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1747\" data-linkid=\"1747\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1747\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">62<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1747\" data-linkid=\"1747\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1747\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">40<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/bnf.nice.org.uk\/drug-class\/angiotensin-converting-enzyme-inhibitors.html\">ACE inhibitors<\/a><\/td><\/tr><\/table>","media":"","concepts_for_notes":{"2270":{"concept_text":"Drug-induced angioedema without urticaria is most frequently associated with angiotensin converting enzyme inhibitors or, less frequently, angiotensin II receptor blockers","concept_percentile":"91"},"3883":{"concept_text":"Urea and electrolytes should be checked at baseline, within two weeks of initiation and after any change of dose. They should be rechecked at 1, 3, and 6 months after establishing maintenance dose","concept_percentile":"37"},"3884":{"concept_text":"An increase in serum creatinine up to 30% from baseline is acceptable when initiating ACE inhibitor treatment","concept_percentile":"83"},"5266":{"concept_text":"ACE inhibitor causes hyperkalaemia ","concept_percentile":"57"},"10496":{"concept_text":"ACE inhibitors - contraindicated in patients with renovascular disease","concept_percentile":"77"},"10906":{"concept_text":"After starting an ACE inhibitor, significant renal impairment may occur if the patient has undiagnosed bilateral renal artery stenosis","concept_percentile":"89"}},"category_name":"Cardiovascular","subcategory_name":"Cardiology","comment_count":6},"",[]]